Setogepram

Setogepram
Clinical data
Other names	PBI-4050, Fezagepras
Identifiers
	IUPAC name 2-(3-pentylphenyl)acetic acid;
CAS Number	1002101-19-0 ;
PubChem CID	24749700 ;
IUPHAR/BPS	10043 ;
DrugBank	DB15447 ;
ChemSpider	58107628 ;
UNII	879OVM0Y1S ;
ChEMBL	ChEMBL4297635 ;
Chemical and physical data
Formula	C13H18O2
Molar mass	206.285 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CCCCCC1=CC(=CC=C1)CC(=O)O;
	InChI InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15); Key:PEGQOIGYZLJMIB-UHFFFAOYSA-N;

Last updated June 30, 2025

Setogepram (PBI-4050, Fezagepras) is an experimental drug which acts as a mixed agonist-antagonist for certain free fatty acid receptors, being an agonist at FFAR1 (GPR40) but an antagonist at GPR84. It has antiinflammatory and anti-fibrotic effects and has reached Phase II human clinical trials for treatment of idiopathic pulmonary fibrosis.^[1]^[2]^[3]^[4]^[5]

References

↑ Li Y, Chung S, Li Z, Overstreet JM, Gagnon L, Grouix B, et al. (May 2018). "Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control". JCI Insight. 3 (10). doi:10.1172/jci.insight.120365. PMC 6012516 . PMID 29769449.
↑ Khalil N, Manganas H, Ryerson CJ, Shapera S, Cantin AM, Hernandez P, et al. (March 2019). "Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis". The European Respiratory Journal. 53 (3). doi:10.1183/13993003.00663-2018. PMC 6422836 . PMID 30578394.
↑ Nguyen QT, Nsaibia MJ, Sirois MG, Calderone A, Tardif JC, Fen Shi Y, et al. (January 2020). "PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure". Cardiovascular Research. 116 (1): 171–182. doi:10.1093/cvr/cvz034. PMID 30753422.
↑ Chen LH, Zhang Q, Xie X, Nan FJ (December 2020). "Modulation of the G-Protein-Coupled Receptor 84 (GPR84) by Agonists and Antagonists". Journal of Medicinal Chemistry. 63 (24): 15399–15409. doi:10.1021/acs.jmedchem.0c01378. PMID 33267584.
↑ Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, et al. (May 2018). "A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84". The American Journal of Pathology. 188 (5): 1132–1148. doi:10.1016/j.ajpath.2018.01.009. PMID 29454750.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Li Y, Chung S, Li Z, Overstreet JM, Gagnon L, Grouix B, et al. (May 2018). "Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control". JCI Insight. 3 (10). doi:10.1172/jci.insight.120365. PMC 6012516 . PMID 29769449.

[2] Khalil N, Manganas H, Ryerson CJ, Shapera S, Cantin AM, Hernandez P, et al. (March 2019). "Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis". The European Respiratory Journal. 53 (3). doi:10.1183/13993003.00663-2018. PMC 6422836 . PMID 30578394.

[3] Nguyen QT, Nsaibia MJ, Sirois MG, Calderone A, Tardif JC, Fen Shi Y, et al. (January 2020). "PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure". Cardiovascular Research. 116 (1): 171–182. doi:10.1093/cvr/cvz034. PMID 30753422.

[4] Chen LH, Zhang Q, Xie X, Nan FJ (December 2020). "Modulation of the G-Protein-Coupled Receptor 84 (GPR84) by Agonists and Antagonists". Journal of Medicinal Chemistry. 63 (24): 15399–15409. doi:10.1021/acs.jmedchem.0c01378. PMID 33267584.

[5] Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, et al. (May 2018). "A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84". The American Journal of Pathology. 188 (5): 1132–1148. doi:10.1016/j.ajpath.2018.01.009. PMID 29454750.

[1]

[2]

[3]

[4]

[5]